---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-25-109637"
form_type: "8-K/A"
ticker: "HCWB"
cik: "0001828673"
company_name: "HCW Biologics Inc."
filed_at: "2025-08-18T23:59:59+00:00"
generated_at: "2026-05-17T12:01:20.036740+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# HCW Biologics Q2 net loss narrows to $1.9M; revenue drops 99%, going concern noted

## Summary
- Q2 2025 revenue $6,550 vs $618,854 in Q2 2024 after suspending Wugen license.
- Net loss improved to $1.9M from $15.3M YoY due to $10.4M arbitration legal fees in prior year.
- Closed $5.0M equity offering on May 15, 2025; extinguished $7.7M debt via restructuring.
- Substantial doubt about going concern without additional funding within 12 months.
- Phase 1 trial for HCW9302 in alopecia areata on track for Q3 2025 launch.

## SEC filing metadata
- accession: 0000950170-25-109637
- form_type: 8-K/A
- ticker: HCWB
- cik: 0001828673
- company_name: HCW Biologics Inc.
- filed_at: 2025-08-18T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1828673/000095017025109637/0000950170-25-109637-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1828673/000095017025109637/hcwb-20250814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-25-109637
- JSON: https://secwatch.observer/filing/0000950170-25-109637.json
- Plain text: https://secwatch.observer/filing/0000950170-25-109637.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.